Get the Stockscreener App
98.05
1.48%
-1.47
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Merck Co Inc stock is traded at $98.05, with a volume of 22.42M.
It is down -1.48% in the last 24 hours and up +0.63% over the past month.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
See More
Previous Close:
$99.52
Open:
$98.83
24h Volume:
22.42M
Relative Volume:
2.15
Market Cap:
$248.03B
Revenue:
$63.17B
Net Income/Loss:
$12.15B
P/E Ratio:
54.47
EPS:
1.8
Net Cash Flow:
$14.84B
1W Performance:
-3.87%
1M Performance:
+0.63%
6M Performance:
-24.38%
1Y Performance:
-6.94%
1-Day Range:
$97.90
$99.68
1-Week Range:
$97.82
$102.28
52-Week Range:
$94.48
$134.63
Merck Co Inc Stock (MRK) Company Profile
Name
Merck Co Inc
Sector
Industry
Phone
908-740-4000
Address
2000 GALLOPING HILL ROAD, KENILWORTH, NJ
Compare MRK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
98.05 | 248.03B | 63.17B | 12.15B | 14.84B | 4.77 |
|
LLY
Lilly Eli Co
|
767.76 | 690.46B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
85.00 | 377.54B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
144.47 | 347.83B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
175.58 | 310.27B | 55.53B | 5.12B | 15.62B | 2.88 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Dec-04-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-11-24 | Downgrade | Daiwa Securities | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
| Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Oct-20-23 | Upgrade | UBS | Neutral → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Hold |
| Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-06-23 | Initiated | Jefferies | Buy |
| Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
| Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
| Jun-06-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-16-21 | Initiated | Daiwa Securities | Neutral |
| Dec-13-21 | Downgrade | UBS | Buy → Neutral |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-01-21 | Upgrade | Argus | Hold → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-27-21 | Resumed | Truist | Buy |
| May-20-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
| Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-16-19 | Initiated | SVB Leerink | Outperform |
| Jul-03-19 | Initiated | Mizuho | Buy |
| May-28-19 | Initiated | Goldman | Neutral |
| May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-16-18 | Reiterated | Citigroup | Buy |
| Oct-09-18 | Resumed | Guggenheim | Buy |
| Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
| Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck Co Inc Stock (MRK) Latest News
Merck - Contract Pharma
Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows - AOL
Why Viking Therapeutics Tumbled by More Than 10% This Week - The Motley Fool
Merck & Co., Inc. (NYSE:MRK) Trading Down 0.8%Time to Sell? - MarketBeat
Merck: LM-299 antibody agreement finalized - Marketscreener.com
BMO cuts rating on Merck and Biogen, on lack of near term catalyst - Investing.com
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
BMO Capital Markets Downgrades Merck & Co., Inc. (NYSE:MRK) to Market Perform - MarketBeat
Merck’s doravirine/islatravir combo yields positive results in Phase 3 HIV-1 trials - World Pharmaceutical Frontiers
Merck secures global rights to novel cancer therapy - Investing.com
Is Merck & Co. (MRK) a Cheap NYSE Stock to Invest in Now? - Insider Monkey
Merck & Co buoyed by Phase III results with HIV tablet - The Pharma Letter
Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet - Simply Wall St
Merck Secures Global Rights to Novel Cancer Drug in $3.3B Licensing Deal with LaNova - StockTitan
Analyst recommendations: Fedex, Merck, Nike, Coinbase, Tesla... - Marketscreener.com
Merck stock downgraded by BMO amid Gardasil, Keytruda concerns - Investing.com
Merck & Co Inc (MRK) DCF Valuation: Is The Stock Undervalued? - The Acquirer's Multiple
Merck & Co. Inc. stock outperforms competitors on strong trading day - MarketWatch
Merck & Co., Inc. (NYSE:MRK) Shares Up 0.5%What's Next? - MarketBeat
Merck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials - Benzinga
Merck & Co (MRK) technical analysisMerck & Co (NYSE:MRK), Hansoh Pharmaceutical Gr (OTC:HNSPF) - Benzinga
Merck: encouraging phase III results in HIV - Marketscreener.com
Merck's HIV treatment meets main goal in two late-stage studies - Reuters
Merck Buys $50 Million of Personalis Stock - Marketscreener.com
Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna - Yahoo Finance
Merck shares reaffirm Market Perform rating on global in-licensing - Investing.com
Merck: Healthcare Pharma Giant: 3.2% Yield, 9.3% 5-Year Dividend Growth, Buy Time - Seeking Alpha
Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug - Yahoo Finance
Merck’s RSV antibody could soon paddle into the rough waters of a crowded market - PharmaVoice
Merck's HIV-1 treatment meets efficacy in Phase 3 trials - Investing.com
Merck's HIV treatment meets main goal of two late-stage studies - Marketscreener.com
Merck stock slips after trial data for HIV drug (MRK:NYSE) - Seeking Alpha
Merck gets rights to Hansoh Pharma’s investigational diabetes drug - World Pharmaceutical Frontiers
Merck (MRK) Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir - StreetInsider.com
Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection - Business Wire
Why Is Merck & Co., Inc. (MRK) Among the Best Dividend Stocks to Invest In? - Yahoo Finance
Merck snags Chinese obesity drug in nearly $2 billion deal - Fortune
Merck (MRK) Stock Moves -1.72%: What You Should Know - Yahoo Finance
Merck strikes a $2B GLP-1 deal with Hansoh - BioWorld Online
Deal Watch: Merck Decides Better Late Than Never In GLP-1 Deal With Hansoh - Citeline News & Insights
Merck & Co. Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Merck & Co., Inc. (NYSE:MRK) Trading Up 0.4%Still a Buy? - MarketBeat
Merck reaches weight-loss drug deal worth up to $2 billion with China-based Hansoh - Yahoo Finance
Merck & Co. taps Chinese biotech for entry into oral GLP-1 arena - FirstWord Pharma
Merck & Co buys in oral GLP-1 RA from China’s Hansoh - The Pharma Letter
Spotlight On: Merck enters the obesity game — four key takeaways - FirstWord Pharma
What's Going On With Viking Therapeutics Stock On Wednesday? - Yahoo Finance
Merck Acquires Potential Weight Loss Drug for $2 Billion - GuruFocus.com
Merck moves into obesity with deal for Hansoh’s GLP-1 pill - BioPharma Dive
Merck in global license agreement with Hansoh Pharma for weight-loss drug - ShareCast
Elon Musk, Netflix fined, Merck's GLP-1 deal: Market Minute - Yahoo Finance
Merck Co Inc Stock (MRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):